1332329-27-7

Debio 0617B, a multi-kinase inhibitor, reduces maintenance and self-renewal of primary human AML CD34+?stem/progenitor cells. Debio 0617B has a unique profile targeting key kinases upstream of STAT3/STAT5 signaling such as JAK, SRC, ABL, and class III/V receptor tyrosine kinases (TKs). Debio 0617B has documented efficacy in STAT3-driven solid tumors[1].

[1] Maximilien Murone,?et al. The Multi-kinase Inhibitor Debio 0617B Reduces Maintenance and Self-renewal of Primary Human AML CD34+?Stem/Progenitor Cells. Mol Cancer Ther.?2017 Aug;16(8):1497-1510. DOI:10.1158/1535-7163.MCT-16-0889